- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02989649
Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice
A Prospective, Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The drug being studied in this study is called alogliptin and alogliptin FDCs. Alogliptin and alogliptin FDCs is being researched to treat people who have diabetes mellitus type 2. This study will look at the glycosylated hemoglobin (HbA1c) level dynamics in participants with diabetes mellitus type 2.
The study enrolled 593 patients. Alogliptin and alogliptin FDCs will be prescribed by the physician as part of participants' T2DM treatment program (independent of participation in this study).
This multi-center study will be conducted in China. The overall duration of study for observation will be approximately 6 months, or up to loss to follow-up or death, whichever occurs first. Participants will make multiple visits to the clinic as per regular doctor's appointments.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
-
-
Hubei
-
Wuhan, Hubei, China
-
-
Liaoning
-
Dalian, Liaoning, China
-
Shenyang, Liaoning, China
-
-
Shandong
-
Jinan, Shandong, China
-
Qingdao, Shandong, China
-
Tai'an, Shandong, China
-
Taian, Shandong, China
-
-
Tianjin
-
Tianjin, Tianjin, China
-
-
-
-
-
Sai Ying Pun, Hong Kong
-
Sha Tin, Hong Kong
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Has a diagnosis of T2DM.
- Has made the decision, along with his/her treating physician, to begin treatment with alogliptin or alogliptin fixed-dose combinations (FDCs).
- Has an glycated hemoglobin (HbA1c) value recorded at most 3 months before initiation of treatment with alogliptin or alogliptin FDCs.
- Alogliptin or alogliptin FDCs is prescribed according to the approved label for China and Hong Kong.
Exclusion Criteria:
- Has gestational diabetes or type 1 diabetes mellitus.
- Has used Dipeptidyl peptidase-4 inhibitors (DPP-IV inhibitors) or Glucagon like peptide-1 agonists (aGLP-1) within the 3 months prior to the start of alogliptin or alogliptin FDCs treatment.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Alogliptin or Alogliptin Fixed Dose Combinations (FDCs)
Participants with type 2 diabetes mellitus (T2DM) who received alogliptin or alogliptin FDCs, orally, prescribed by the physician as part of participants' T2DM treatment program (independent of participation in this study) were observed for approximately 6 months, or up to loss to follow-up or death, whichever occurred first.
|
Alogliptin tablets
Alogliptin FDC with pioglitazone tablets
Alogliptin FDC with metformin tablets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Glycosylated Hemoglobin (HbA1c) Level at Month 6
Time Frame: Baseline and Month 6
|
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Month 6 relative to baseline.
Glycosylated hemoglobin (HbA1c) as a diagnostic criteria of diabetes mellitus is ≥6.5%.
A negative change from Baseline indicates improvement.
|
Baseline and Month 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Glycosylated Hemoglobin (HbA1c) Level at Month 6 in Subgroups of Participants With Different Clinical Characteristics
Time Frame: Baseline and Month 6
|
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Month 6 relative to baseline.
Glycosylated hemoglobin (HbA1c) as a diagnostic criteria of diabetes mellitus is ≥6.5%.
Subgroups included participants with different baseline clinical characteristics with predictors such as prior therapy of diabetes mellitus, sex, age group, cardiovascular risk group, therapy type (monotherapy or combined therapy), baseline body mass index (BMI) and initial glycemic control.
A negative change from Baseline indicates improvement.
|
Baseline and Month 6
|
Percentage of Participants With a Decrease in HbA1c Level by <7.0%
Time Frame: Baseline and Month 6
|
Percentage of participants with a decrease of <7.0% from baseline in HbA1c were reported.
|
Baseline and Month 6
|
Percentage of Participants With a Decrease in HbA1c Level by >0.3% and No Tolerability Findings
Time Frame: Baseline and Month 6
|
Percentage of participants with a decrease of >0.3% from baseline in HbA1c along with no tolerability findings were reported.
Tolerability findings included hypoglycemic event, or weight gain ≥5%.
|
Baseline and Month 6
|
Change From Baseline in Fasting Plasma Glucose (FPG) Level Over Time
Time Frame: Baseline and Months 3 and 6
|
The change between the fasting plasma glucose value collected at Months 3 and 6 relative to baseline.
A negative change from Baseline indicates improvement.
|
Baseline and Months 3 and 6
|
Change From Baseline in Glycosylated Hemoglobin (HbA1c) Level Over Time
Time Frame: Baseline and Months 3 and 6
|
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Months 3 and 6 relative to baseline.
A negative change from Baseline indicates improvement.
|
Baseline and Months 3 and 6
|
Number of Participants With Adverse Drug Reactions (ADRs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)
Time Frame: Baseline up to Month 6
|
An ADR is defined as any response to a medicinal product that is noxious and unintended and that occurs at doses normally used in humans for the prophylaxis, diagnosis, or therapy of diseases or for the restoration, correction, or modification of physiological function.
An SAE is defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important due to other reasons than the above mentioned criteria.
Adverse events such as pancreatitis, hepatic disorders, and hypersensitivity reactions (including angioedema, anaphylaxis, and Stevens-Johnson syndrome) were considered as AESI.
|
Baseline up to Month 6
|
Percentage of Participants Who Remain on Treatment With Alogliptin or Alogliptin FDCs
Time Frame: Months 3 and 6
|
Months 3 and 6
|
|
Time to Alogliptin or Alogliptin FDCs Dose Escalation or Dose Reduction
Time Frame: Months 3 and 6
|
Months 3 and 6
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protease Inhibitors
- Incretins
- Dipeptidyl-Peptidase IV Inhibitors
- Metformin
- Pioglitazone
- Alogliptin
Other Study ID Numbers
- Alogliptin-5009
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Alogliptin
-
Kun-Ho YoonTakedaCompletedType 2 Diabetes MellitusKorea, Republic of
-
TakedaCompletedDiabetes MellitusUnited States, Australia, Brazil, Chile, Guatemala, India, Mexico, New Zealand, Peru, South Africa, Netherlands, Poland, United Kingdom, Argentina, Dominican Republic
-
TakedaCompleted
-
TakedaCompletedDiabetes MellitusUnited States, Australia, Brazil, Chile, Guatemala, India, Mexico, New Zealand, Peru, South Africa, Czech Republic, Germany, Hungary, Netherlands, Poland, Argentina
-
TakedaCompletedDiabetes MellitusUnited States, Australia, Brazil, Chile, Guatemala, India, Mexico, New Zealand, Peru, South Africa, Czech Republic, Germany, Hungary, Netherlands, Poland, United Kingdom, Argentina
-
Kun-Ho YoonTakedaTerminated
-
TakedaCompletedDiabetes MellitusChina, Taiwan, Korea, Republic of, Malaysia
-
TakedaCompletedDiabetes MellitusNetherlands, Sweden
-
Seoul National University HospitalUnknownType 2 Diabetes Mellitus
-
TakedaCompleted